SCP
EVMN

SymBiosis Capital Partners’s Evommune Inc EVMN Stock Holding History

SymBiosis Capital Partners’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.4M Hold
1,280,778
– – 55.8% 1
2025
Q4 		$21.9M Buy
+1,280,778
New +$24.1M 20.03% 1

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SymBiosis Capital Partners's EVMN Position: Q1 2026 in Review

SymBiosis Capital Partners held its Evommune Inc (EVMN) position steady in Q1 2026 at 1,280,778 shares worth $29.4M. The position accounts for 55.8% of the portfolio, ranked #1.

SymBiosis Capital Partners first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • SymBiosis Capital Partners held 1,280,778 shares of Evommune Inc worth $29.4M as of Q1 2026.
  • SymBiosis Capital Partners left its Evommune Inc share count unchanged in Q1 2026.
  • Evommune Inc made up 55.8% of SymBiosis Capital Partners's portfolio in Q1 2026, its #1 holding.
  • SymBiosis Capital Partners first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.